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lies at the nexus of a variety of previously
known hair follicle regulators (Figure 1).
Butcher predicted that knowledge of
hair cycling would provide insight into
the workings of other organs. Studies
of NFAT, a well-characterized signaling
pathway in the immune system, have re-
vealed important details regarding hair
cycling and have also stimulated many
additional questions. Future studies will
need to identify other environmental influ-
ences that effect pathway-mediated qui-
escence. In particular, because NFAT
nuclear activity depends on intracellular
calcium levels, a greater understanding
is needed of calcium regulation in stem
cells. Moreover, the role of other known
hair cycle regulators, such as Sonic
hedgehog or Wnt, in regulating stem cell
cycling needs to be further elucidated.
Wnt-induced stem cell activation occurs
in the presence of nuclear NFAT, suggest-
ing the existence of an NFAT-independent
pathway for overcoming quiescence.
Finally, BMP-dependent NFAT expres-
sion affects cycling, but not differentiation,
arguing for the existence of an unidentified
NFAT-independent differentiation path-
way downstream of BMP. With the current
pace of advances in understanding how
hair follicle stem cells are regulated, stud-
ies of hair cycling will likely contribute
greatly to studies of how other stem cells
are regulated as well.
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Accumulating information indicates that mesenchymal stem or stromal cells (MSCs) are immunomodulatory,
but the data to explain the observations are frequently conflicting. In this issue of Cell Stem Cell, Ren et al.
(2008) provide evidence for a possible underlying mechanism of MSC-mediated T cell suppression. A
perspective for considering these interesting observations is discussed.Mesenchymal stem cells, or as they have
been termed more recently, mesenchy-
mal stromal cells (MSCs) (Horwitz et al.,
2005) are a fascinating component of the
microenvironment in the bone marrow
and other tissues, and for many years
they were thought to have a predominantly
supportive role. The focus of studies with
MSCs over the past decade, however,
has shifted dramatically, first to their pos-
sible role in tissue regeneration via broad,
multilineage differentiation potential, and
more recently, to a further characteriza-
tion of their immunomodulatory properties
(Keating, 2006; Nauta and Fibbe, 2007).
A better understanding of the mecha-
nisms underlying the immunomodulatory106 Cell Stem Cell 2, February 2008 ª2008effects of MSCs is important on two
counts. First, it may uncover a poorly un-
derstood arm of the immune system, and
second, it carries profound therapeutic im-
plications. MSCs have the potential to ef-
fectively treat immune-mediated diseases
refractory to front-line medical therapy, in-
cluding acute graft-versus-host disease
(GvHD), a frequently serious condition
that occurs after allogeneic hematopoietic
cell transplantation. This area of investiga-
tion, however, and the basis of MSC-medi-
ated T cell suppression in particular, has
been bedeviled by conflicting data.
The study by Ren et al. (2008) in this
issue provides a timely and important
contribution to the ongoing debate aboutElsevier Inc.how MSCs suppress T cells and enables
a clearer picture of the mechanism to
emerge. Previous work by several groups
had established that MSCs inhibit the
proliferation of T cells induced by alloanti-
gens and nonspecific mitogens and that
the inhibition is not genetically restricted
(reviewed in Keating, 2006). Moreover, a
number of studies show that the suppres-
sion is variably sustained in transwell
experiments, suggesting that a soluble
factor(s) is involved, although other inves-
tigators claim a requirement for MSC-T
cell contact (Krampera et al., 2003). Re-
sults have also been divergent in other
in vitro experiments: one group implicated
transforming growth factor-b (TGF-b) and
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PreviewsFigure 1. Possible Mechanism of MSC-Mediated T Cell Suppression
Inflammation, injury, or alloresponse leads to T cell activation. Activated T cells (light blue) release proinflammatory cytokines, IFNg, TNFa, IL-1a, and IL-1b (blue
crosses), which target MSCs. The cytokines (IFNg plus any one of TNFa, IL-1a, or IL-1b) trigger release of chemokines (green) and, in an independent manner, NO
(orange) from MSCs. Chemokines recruit CXCR3R+ immune cells, including T cells (lavender), to the vicinity of MSCs. NO from MSCs suppresses nearby T cells
(purple) by inhibiting Stat5 phosphorylation, leading to cell-cycle arrest. Based on the studies by Ren et al. (2008) and Sato et al. (2007).hepatocyte growth factor (Di Nicola et al.,
2002), another posited a role for inter-
leukin-2 and interleukin-10 (Rasmusson
et al., 2005), while several contended that
prostaglandin E2 is involved (Nauta and
Fibbe, 2007). Yet another possibility is
interferon-g (IFNg)-mediated induction of
MSC-derived indoleamine 2,3-dioxyge-
nase (IDO), which catabolizes tryptophan,
leading to suppression of T cell prolifera-
tion and apoptosis of activated T cells
(Keating, 2006; Nauta and Fibbe, 2007).
More recently, Sato et al. (2007) showed
that the suppressive effect is triggered
downstream of the T cell receptor com-
plex. Their work provided evidence that
MSCs produce nitric oxide (NO) in a
dose-dependent manner in response to
CD4+ or CD8+ T cells and indicated that
NO is involved in the suppression of Stat5
phosphorylation in T cells with a conse-
quent reduction in T cell proliferation.
The group also showed that inhibiting
prostaglandin sythase or nitric oxide syn-
thase (NOS) restored T cell proliferation,
whereas an inhibitor of IDO or a neutraliz-
ing antibody to TGF-b did not.
Ren et al. (2008) have confirmed the
Sato data and extended the observations
to provide a coherent mechanism (Fig-
ure 1). They employed an attractive com-
bination of conventional immune assays,
inhibitor studies, and the use of MSCs
derived from knockout mice targeting ei-
ther the IFNg receptor or inducible NOS.
They showed that the immunosuppres-
sion is mediated by INFg combined with
any one of the proinflammatory cytokines,TNFa, IL-1a, or IL-1b. They also demon-
strated that such combinations lead to
the release, independently, of NO and
chemokines from MSCs. The chemokines
serve to attract immune cells to the vicin-
ity, including T cells, which express the
chemokine receptor CXCR3. The NO
serves to suppress the proliferation of
neighboring T cells to create an apparent
negative feedback loop, dampening an
overzealous immune response to inflam-
mation, injury, or a brisk alloresponse. In
contrast to other investigators, the au-
thors were unable to abrogate immune
suppression with indomethacin, a prosta-
glandin synthase inhibitor, but confirmed
the work of others that an IDO inhibitor
or neutralizing antibodies against IL-10
or TGF-b do not affect suppression. Inter-
estingly, in transwell experiments, they
were unable to show the suppressive
effect of NO and accounted for this obser-
vation on the basis of the rapidly diminish-
ing concentration of the active form from
the cell source.
Ren et al. also demonstrated that NO
production is necessary for MSC-medi-
ated immune suppression in vivo. In the
absence of NO, the chemokine-mediated
recruitment of immune cells by iNOS/
MSCs coinjected with ovalbumin into the
footpad of ovalbumin-immunized wild-
type mice resulted in enhanced inflam-
mation, in contrast to similar studies with
wild-type MSCs that demonstrated a
marked reduction in leukocyte infiltrates.
An additional valuable contribution by
Ren et al. was to investigate the basisCell Stem Cfor the exciting clinical observations by
Le Blanc and colleagues, who docu-
mented the successful treatment of med-
ically refractory severe acute GvHD with
MSC infusions (Le Blanc et al., 2004). In
a mouse GvHD model, Shi’s group
showed that, in contrast to animals
treated with wild-type MSCs (which ex-
hibited reduced GvHD), MSCs lacking
either the IFNg receptor or iNOS had the
same poor outcomes as untreated posi-
tive control mice.
Although the role of the elaborated che-
mokines is important and novel, these ob-
servations place IFNg, and especially NO,
squarely at the center of events underly-
ing MSC-mediated immune suppression,
including effects on acute GvHD. But
how does NO work in this context? Oza-
wa’s group (Sato et al., 2007) has argued
that NO inhibits Stat5 phosphorylation in
T cells, leading to cell-cycle arrest. The ef-
fects of NO may be more complex in this
system, however, given that it acts not
only via the JAK/STAT pathway but also
on the MAPK and NF-kB pathways and
may affect apoptosis of immune cells as
well as downregulate the gene expression
of a variety of cytokines (Coleman, 2001).
The Ren study suggests that further re-
search is needed to better understand
the signaling events that lead to NO-medi-
ated immune suppression by MSCs. It is
to be hoped that this work will also stimu-
late mechanistic studies involving other
immune cells that are known to be af-
fected by MSCs, including regulatory T
cells, NK cells, dendritic cells, and B cells,ell 2, February 2008 ª2008 Elsevier Inc. 107
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Previewsin order to obtain a more complete picture
of this complex phenomenon.
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spermatogonia.
The main function of the germinal lineage
is to maintain the integrity of the genome
in order to prevent reproduction failure
and to limit hereditary risk when transmit-
ted to progeny. DNA damage responses
involve the survey of DNA, and repair of
damage using signal transduction path-
ways that regulate cell-cycle checkpoints
and/or apoptosis to eliminate unrepaired
DNA-damaged cells. Defects in the DNA
damage response are the hallmarks of
cancers, premature aging syndromes,
abnormal development, and meiosis
impairment. All cells are subject to endog-
enous and exogenous genotoxic stress,
but the DNA damage response is particu-
larly important for stem cells in order to
maintain the stability of their genome
throughout the adult life of the organism,
as demonstrated for hematopoietic stem
cells (reviewed in Kenyon and Gerson,
2007). This importance is underscored
in germline stem (GS) cells due to their
dual function as stem cells and as the
guardians of the integrity of the heritable
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involved in maintaining the stem
genome. In this issue, Takubo et al.
(2008) show that ataxia telangiectasia-
mutated (ATM), a central protein of the
DNA damage response, regulates the
maintenance of the stem cell potential
of undifferentiated spermatogonia in
testis.
Spermatogenesis is a step-wise process
that requires coordination of mitosis, meio-
sis, and spermiogenesis, the process by
which haploid spermatids mature into
sperm. In an adult mouse testis, there are
3000–4000 GS cells—also called Asingle
(As) spermatogonia. These stem cells can
self-renew or differentiate into committed
paired (Ap) and aligned (Aal) spermatogo-
nia, which will in turn pursue their differen-
tiation processes. GS cells and committed
Ap and Aal spermatogonia are collectively
called undifferentiated spermatogonia.
The presence of GS cells in testes was
clearly demonstrated by recovery of sper-
matogenesis after transplantation of donor
testicular cells into the testis of sterile male
mice, and the reconstituting colony-form-
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l for ensuring DNA integrity during
how that ATM, a key kinase of the
cell potential of undifferentiated
ing activity was found in the undifferenti-
ated spermatogonial population (Shino-
hara et al., 2000). Nakagawa et al. (2007)
recently suggested, however, that the
immediate descendants of the GS cells,
i.e., committed Ap spermatogonia, could
also retain colony-forming activity after
transplantation, introducing the notion
that these early progenitors could act as
‘‘potential stem cells.’’
ATM, a protein kinase of the phosphati-
dyl-inositol 3-kinase family, is activated
by DNA double-strand breaks, where-
upon it phosphorylates key substrates
such as p53 and Chk2, which regulate
cell-cycle checkpoints, DNA repair, and
apoptosis. Ataxia-telangiectasia (AT) pa-
tients, in which Atm is inactivated, are
characterized by a progressive cerebellar
ataxia, oculocutaneous telangiectasia,
immune deficiency, premature aging,
increased risks of lymphoma, and go-
nadal atrophy. ATM is also involved in
hematopoietic stem cell defects (Ito
et al., 2004).
